½ÃÀ庸°í¼­
»óǰÄÚµå
1589600

¼¼°èÀÇ Drug Discovery ¾Æ¿ô¼Ò½Ì ½ÃÀå : ¿öÅ©Ç÷οì, Ä¡·á ¿µ¿ª, À¯Çü, ÃÖÁ¾ »ç¿ëÀÚº° ¿¹Ãø(2025-2030³â)

Drug Discovery Outsourcing Market by Workflow, Therapeutics Area, Type, End-User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 195 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Drug Discovery ¾Æ¿ô¼Ò½Ì ½ÃÀåÀÇ 2023³â ½ÃÀå ±Ô¸ð´Â 40¾ï 1,000¸¸ ´Þ·¯·Î, 2024³â¿¡´Â 43¾ï 8,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 9.39%·Î ¼ºÀåÇØ 2030³â¿¡´Â 75¾ï 3,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Drug Discovery ¾Æ¿ô¼Ò½ÌÀÇ Á¶»ç ¹üÀ§´Â ÀǾàǰÀÇ ¿¬±¸ °³¹ß ÇÁ·Î¼¼½º¸¦ ¿ÜºÎ Àü¹® ±â°ü¿¡ À§Å¹ÇÏ´Â °ÍÀÔ´Ï´Ù. Drug DiscoveryÀº º¹ÀâÇÏ°í ºñ¿ëÀÌ ¸¹ÀÌ µé°í ½Ã°£ÀÌ ¸¹ÀÌ ¼Ò¿äµÇ¹Ç·Î Á¦¾à ȸ»ç´Â ¿ÜºÎ Àü¹® Áö½ÄÀ» Ȱ¿ëÇÏ¿© ¸®¼Ò½º¸¦ ÃÖÀûÈ­Çϰí ÀÏÁ¤À» ´ÜÃàÇØ¾ß ÇÕ´Ï´Ù. ¾Æ¿ô¼Ò½ÌÀº ´ë»ó °ËÁõ ¹× ¸®µå ÃÖÀûÈ­ºÎÅÍ ÀüÀÓ»ó ¹× ÀÓ»ó½ÃÇè °ü¸®¿¡ À̸£±â±îÁö ÀǾàǰ °³¹ßÀÇ ´Ù¾çÇÑ ´Ü°è¿¡¼­ Àû¿ëµË´Ï´Ù. ÃÖÁ¾ ¿ëµµ·Î´Â Á¦¾àȸ»ç, »ý¸í°øÇбâ¾÷, Çмú¿¬±¸±â°ü, CRO(ÀǾàǰ°³¹ß¾÷¹«¼öʱâ°ü) µîÀÌ ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 40¾ï 1,000¸¸ ´Þ·¯
¿¹Ãø³â(2024) 43¾ï 8,000¸¸ ´Þ·¯
¿¹Ãø³â(2030) 75¾ï 3,000¸¸ ´Þ·¯
CAGR(%) 9.39%

½ÃÀå ÀλçÀÌÆ®¿¡ µû¸£¸é Á¦¾à±â¾÷¿¡ ÀÇÇÑ ¿¬±¸°³¹ßºñ Áõ°¡, ±¤¹üÀ§ÇÑ Á¶»ç¸¦ ÇÊ¿ä·Î ÇÏ´Â ¾ö°ÝÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©, »õ·Î¿î Ä¡·á±â¼úÀÇ ÃâÇöÀÌ Å« ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ÁÖ¿ä ¿µÇâ¿äÀÎÀ¸·Î´Â À¯ÀüÀÚ ¿¬±¸¿Í »ý¸í °øÇÐ ¿¬±¸ÀÇ Áøº¸, Çõ½ÅÀûÀÎ Ä¡·á¹ýÀÌ ÇÊ¿äÇÑ ¸¸¼º Áúȯ Áõ°¡, ¿¬±¸ ÀηÂÀÇ ¼¼°èÈ­ µîÀÌ ÀÖ½À´Ï´Ù. °³ÀÎÈ­µÈ ÀÇ·á, »ý¹°ÇÐÀû Á¦Á¦ ¹× À¯ÀüüÇÐ ºÐ¾ß¿¡¼­ ¸ÂÃãÇü ¾Æ¿ô¼Ò½Ì ¸ðµ¨Àº °æÀï ¿ìÀ§¸¦ °¡Á®¿Ã ¼ö ÀÖ½À´Ï´Ù. Çаè¿Í »ê¾÷°è °£ÀÇ Çù¾÷Àº Çõ½Å°ú »ó¾÷È­ÀÇ °ÝÂ÷¸¦ ¸Þ¿ì¸é¼­ ´õ¿í ¼ºÀåÀ» °¡¼ÓÇÒ ¼ö ÀÖ½À´Ï´Ù.

±×·¯³ª ÁöÀûÀç»êÀÇ °ü¸®, Áö¿ªÁ¤¼¼º° ǰÁú°ü¸®, Áö¿ª¿¡ µû¶ó ´Ù¸¥ ±ÔÁ¦»óȲ¿¡ ´ëÇÑ ´ëÀÀ µîÀÌ °úÁ¦°¡ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¾Æ¿ô¼Ò½Ì ÆÄÆ®³ÊÀÇ ½Å·Ú¼º°ú Àü¹® Áö½Ä¿¡ ´ëÇÑ ÀÇÁ¸°ú ÀÇ»ç ¼ÒÅëÀ» ¹æÇØÇÏ´Â ½ÃÂ÷ÀÇ °¡´É¼ºÀ¸·Î ÀÎÇØ ÇѰ谡 ¹ß»ýÇÕ´Ï´Ù.

½ÃÀåÀÇ ÀáÀç·ÂÀ» Ȱ¿ëÇϱâ À§Çؼ­´Â ÀΰøÁö´É°ú ¸Ó½Å·¯´×À» ÅëÇÕÇÏ¿© Drug DiscoveryÀÇ ¿¹Ãø ºÐ¼®À» ½Ç½ÃÇϰí, µ¥ÀÌÅÍ °ü¸® Àü·«À» °­È­Çϰí, ±×¸° Äɹ̽ºÆ®¸®¿¡ ÅõÀÚÇÏ¿© Áö¼Ó °¡´ÉÇÑ ÀǾàǰ Á¦Á¶ ¹æ¹ýÀ» °³¹ßÇÕ´Ï´Ù. ÀÏ¿¡ Çõ½ÅÀ» ÁýÁßÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÇÏÀÌÅ×Å© ±â¾÷°úÀÇ ÆÄÆ®³Ê½ÊÀ» Ű¿ö µðÁöÅÐ °Ç°­°ú ¿ø°Ý ÀÇ·á ¼Ö·ç¼ÇÀÇ Áøº¸¸¦ ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù. ½ÃÀåÀº ¿ªµ¿ÀûÀÌ¸ç ±ÔÁ¦, Çõ½Å, °æÀïÀÌ ²÷ÀÓ¾øÀÌ ¼¯¿© ÀÖ½À´Ï´Ù. µû¶ó¼­ ¼ºÀå¼¼¸¦ À¯ÁöÇÏ°í »õ·Î¿î ±âȸ¸¦ Ȱ¿ëÇϱâ À§Çؼ­´Â Çù·Â°ú ±â¼ú ÅëÇÕ¿¡ ÃÊÁ¡À» ¸ÂÃá Àü·«Àû Á¢±ÙÀÌ ÇÊ¿äÇÕ´Ï´Ù.

½ÃÀå ¿ªÇÐ: ±Þ¼ÓÈ÷ ÁøÈ­ÇÏ´Â Drug Discovery ¾Æ¿ô¼Ò½Ì ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

ÀǾàǰ ¾Æ¿ô¼Ò½Ì ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿Àû ÀÎ »óÈ£ ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ðÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÅõÀÚ°áÁ¤, Àü·«Àû °áÁ¤ Á¤¹ÐÈ­, »õ·Î¿î ºñÁî´Ï½º ±âȸ ȹµæ¿¡ ´ëºñÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦ÀûÀÎ ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ½°ú µ¿½Ã¿¡, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ëÀ̳ª ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ´Ù¾çÇÑ ¸¸¼ºÁúȯ Áõ°¡¿Í ÇコÄɾî ÁöÃâ Áõ°¡
    • ÀǾàǰ R&D ÅõÀÚ Áõ°¡
    • Á¦³×¸¯ ÀǾàǰ°ú »ý¹°ÇÐÀû Çõ½Å¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ¾Æ¿ô¼Ò½Ì ½Ã ÄÄÇöóÀ̾𽺠¹®Á¦
  • ½ÃÀå ±âȸ
    • ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ÁÖ¸ñÀÇ °íÁ¶
    • »ý¹° Á¦Á¦ ÆÄÀÌÇÁ¶óÀÎ Áõ°¡¿Í Á¦Á¶ À§Å¹ ¼­ºñ½ºÀÇ È®´ë
  • ½ÃÀåÀÇ °úÁ¦
    • ¾ö°ÝÇÑ Á¤ºÎ ±ÔÁ¦

Portre's Five Forces: Drug Discovery ¾Æ¿ô¼Ò½Ì ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces 'ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÆÄ¾ÇÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces Framework´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ޱ¸ÇÏ´Â ¸íÈ®ÇÑ ±â¼úÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂûÀ» ÅëÇØ ±â¾÷Àº ÀÚ»çÀÇ °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ °úÁ¦¸¦ ÇÇÇÒ ¼ö ÀÖÀ¸¸ç, º¸´Ù °­ÀÎÇÑ ½ÃÀå¿¡¼­ÀÇ Æ÷Áö¼Å´×À» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : Drug Discovery ¾Æ¿ô¼Ò½Ì ½ÃÀå¿¡¼­ ¿ÜºÎ·ÎºÎÅÍÀÇ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº Drug Discovery ¾Æ¿ô¼Ò½Ì ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀÎ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¾ÕÀ¸·Î ¿¹»óµÇ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : Drug Discovery ¾Æ¿ô¼Ò½Ì ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

Drug Discovery ¾Æ¿ô¼Ò½Ì ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀï Æ÷Áö¼Å´×À» ¹àÈú ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í º¥´õµéÀº °æÀïÀÌ Ä¡¿­ÇØÁö´Â °¡¿îµ¥ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : Drug Discovery ¾Æ¿ô¼Ò½Ì ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â Drug Discovery ¾Æ¿ô¼Ò½Ì ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ Çà·ÄÀ» ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº °ø±Þ¾÷üÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±âÁØÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ¸Â´Â ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·«ºÐ¼®°ú Ãßõ : Drug Discovery ¾Æ¿ô¼Ò½Ì ½ÃÀå¿¡¼­ ¼º°øÀ» À§ÇÑ ±æÀ» ±×¸®±â

Drug Discovery ¾Æ¿ô¼Ò½Ì ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ ÇÁ·¹Á𽺠°­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÎ ¿ä¼ÒÀÔ´Ï´Ù. ÀÌ Á¢±Ù¹ýÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö ÀÖ´Â ½Ã½ºÅÛÀ» ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ: ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­: ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ¡¤Ã¶¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ´Ù¾çÇÑ ¸¸¼º ÁúȯÀÇ ÀÌȯÀ²ÀÇ »ó½Â°ú ÇコÄɾîºñ Áõ°¡
      • ÀǾàǰ R&D ÅõÀÚ Áõ°¡
      • Á¦³×¸¯ ÀǾàǰ°ú »ý¹°ÇÐÀû Çõ½Å¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
    • ¾ïÁ¦¿äÀÎ
      • ¾Æ¿ô¼Ò½Ì ½Ã ÄÄÇöóÀ̾𽺠¹®Á¦
    • ±âȸ
      • ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ÁÖ¸ñÀÇ °íÁ¶
      • ¹ÙÀÌ¿ÀÀǾàǰ ÆÄÀÌÇÁ¶óÀÎ Áõ°¡¿Í ¼öŹ Á¦Á¶ ¼­ºñ½ºÀÇ È®´ë
    • °úÁ¦
      • ¾ö°ÝÇÑ Á¤ºÎ ±ÔÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦
    • »ç±³
    • ±â¼úÀû
    • ¹ý·ü»ó
    • ȯ°æ

Á¦6Àå Drug Discovery ¾Æ¿ô¼Ò½Ì ½ÃÀå : ¿öÅ©Ç÷ο캰

  • ¸®µå ½Äº° ¹× Èĺ¸ÀÚ ÃÖÀûÈ­
  • ÀÓ»ó Àü °³¹ß
  • Ÿ°Ù ½Äº° ¹× ½ºÅ©¸®´×
  • Ÿ°Ù °ËÁõ ¹× ±â´É Á¤º¸ÇÐ

Á¦7Àå Drug Discovery ¾Æ¿ô¼Ò½Ì ½ÃÀå : Ä¡·á ¿µ¿ªº°

  • Ç×°¨¿°
  • ½ÉÀåÇ÷°ü
  • ÁßÃ߽Űæ°è
  • ÇǺΰú
  • ³»ºÐºñ
  • À§Àå
  • ºñ´¢ »ý½Ä±â°è
  • Ç÷¾×ÇÐ
  • ¸é¿ªÁ¶Àý
  • Á¾¾çÇÐ
  • ¾È°ú
  • ÅëÁõ°ú ¸¶Ãë
  • È£Èí±â°è

Á¦8Àå Drug Discovery ¾Æ¿ô¼Ò½Ì ½ÃÀå : À¯Çüº°

  • »ý¹°ÇÐ ¼­ºñ½º
  • È­ÇÐ ¼­ºñ½º

Á¦9Àå Drug Discovery ¾Æ¿ô¼Ò½Ì ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • Çмú±â°ü
  • Á¦¾à ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷

Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ Drug Discovery ¾Æ¿ô¼Ò½Ì ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Drug Discovery ¾Æ¿ô¼Ò½Ì ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦12Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Drug Discovery ¾Æ¿ô¼Ò½Ì ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸ñ·Ï

  • Charles River Laboratories
  • Curia Global, Inc.
  • Dalton Pharma Services
  • Eurofins DiscoverX Products
  • Evotec SE
  • GenScript Biotech Corporation
  • Jubilant Biosys Ltd.
  • Laboratory Corporation of America Holdings
  • Merck & Co., Inc.
  • Oncodesign Precision Medicine
  • PPD Inc.
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec
JHS 24.11.21

The Drug Discovery Outsourcing Market was valued at USD 4.01 billion in 2023, expected to reach USD 4.38 billion in 2024, and is projected to grow at a CAGR of 9.39%, to USD 7.53 billion by 2030.

The scope of drug discovery outsourcing encompasses the delegation of research and development processes in pharmaceuticals to specialized external organizations. This practice is necessitated by the complex, costly, and time-consuming nature of drug discovery, compelling pharmaceutical companies to leverage external expertise to optimize resources and accelerate timelines. Outsourcing is applied across various stages of drug development, from target validation and lead optimization to preclinical and clinical trial management. The end-use scope includes pharmaceutical and biotechnology companies, academic and research institutions, and contract research organizations (CROs).

KEY MARKET STATISTICS
Base Year [2023] USD 4.01 billion
Estimated Year [2024] USD 4.38 billion
Forecast Year [2030] USD 7.53 billion
CAGR (%) 9.39%

Market insights reveal significant growth driven by the increasing R&D expenditure by pharmaceutical companies, stringent regulatory frameworks necessitating extensive research, and the advent of novel therapeutic technologies. Key influencing factors include advancements in genetic and biotechnological research, the rising prevalence of chronic diseases demanding innovative therapies, and the globalization of research talent pools. Opportunities abound in personalized medicine, biologics, and genomics, where tailor-made outsourcing models can offer competitive advantages. Collaborations across academia and industry players can further fuel growth by bridging the gap between innovation and commercialization.

However, challenges include managing intellectual property, maintaining quality control across geographical boundaries, and navigating regulatory landscapes that vary by region. Limitations also arise from dependency on the reliability and expertise of outsourcing partners and potential time zone differences hindering communication.

To capitalize on market potential, innovation could focus on integrating artificial intelligence and machine learning for predictive analytics in drug discovery, enhancing data management strategies, and investing in green chemistry to develop sustainable drug production methodologies. Additionally, nurturing partnerships with tech companies can drive advancements in digital health and telemedicine solutions. The market is dynamic, marked by a constant interplay of regulation, innovation, and competition, which necessitates a strategic approach focusing on collaboration and technological integration to maintain growth momentum and capitalize on emerging opportunities.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Drug Discovery Outsourcing Market

The Drug Discovery Outsourcing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of various chronic diseases coupled with rising healthcare expenditure
    • Increasing pharmaceutical R&D investment
    • Rising demand for generic drugs and biologic innovation
  • Market Restraints
    • Compliance issues while outsourcing
  • Market Opportunities
    • Increased focus on personalized medicine
    • Growing number of biologics pipeline and growing contract manufacturing service
  • Market Challenges
    • Stringent government regulations

Porter's Five Forces: A Strategic Tool for Navigating the Drug Discovery Outsourcing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Drug Discovery Outsourcing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Drug Discovery Outsourcing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Drug Discovery Outsourcing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Drug Discovery Outsourcing Market

A detailed market share analysis in the Drug Discovery Outsourcing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Drug Discovery Outsourcing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Drug Discovery Outsourcing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Drug Discovery Outsourcing Market

A strategic analysis of the Drug Discovery Outsourcing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Drug Discovery Outsourcing Market, highlighting leading vendors and their innovative profiles. These include Charles River Laboratories, Curia Global, Inc., Dalton Pharma Services, Eurofins DiscoverX Products, Evotec SE, GenScript Biotech Corporation, Jubilant Biosys Ltd., Laboratory Corporation of America Holdings, Merck & Co., Inc., Oncodesign Precision Medicine, PPD Inc., Thermo Fisher Scientific Inc., and WuXi AppTec.

Market Segmentation & Coverage

This research report categorizes the Drug Discovery Outsourcing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Workflow, market is studied across Lead Identification & Candidate Optimization, Preclinical Development, Target Identification & Screening, and Target Validation & Functional Informatics.
  • Based on Therapeutics Area, market is studied across Anti-Infective, Cardiovascular, Central Nervous System, Dermatology, Endocrine, Gastrointestinal, Genitourinary System, Hematology, Immunomodulation, Oncology, Ophthalmology, Pain & Anesthesia, and Respiratory System.
  • Based on Type, market is studied across Biology Services and Chemistry Services.
  • Based on End-User, market is studied across Academic Institutes and Pharmaceutical & Biotechnology companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of various chronic diseases coupled with rising healthcare expenditure
      • 5.1.1.2. Increasing pharmaceutical R&D investment
      • 5.1.1.3. Rising demand for generic drugs and biologic innovation
    • 5.1.2. Restraints
      • 5.1.2.1. Compliance issues while outsourcing
    • 5.1.3. Opportunities
      • 5.1.3.1. Increased focus on personalized medicine
      • 5.1.3.2. Growing number of biologics pipeline and growing contract manufacturing service
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent government regulations
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Drug Discovery Outsourcing Market, by Workflow

  • 6.1. Introduction
  • 6.2. Lead Identification & Candidate Optimization
  • 6.3. Preclinical Development
  • 6.4. Target Identification & Screening
  • 6.5. Target Validation & Functional Informatics

7. Drug Discovery Outsourcing Market, by Therapeutics Area

  • 7.1. Introduction
  • 7.2. Anti-Infective
  • 7.3. Cardiovascular
  • 7.4. Central Nervous System
  • 7.5. Dermatology
  • 7.6. Endocrine
  • 7.7. Gastrointestinal
  • 7.8. Genitourinary System
  • 7.9. Hematology
  • 7.10. Immunomodulation
  • 7.11. Oncology
  • 7.12. Ophthalmology
  • 7.13. Pain & Anesthesia
  • 7.14. Respiratory System

8. Drug Discovery Outsourcing Market, by Type

  • 8.1. Introduction
  • 8.2. Biology Services
  • 8.3. Chemistry Services

9. Drug Discovery Outsourcing Market, by End-User

  • 9.1. Introduction
  • 9.2. Academic Institutes
  • 9.3. Pharmaceutical & Biotechnology companies

10. Americas Drug Discovery Outsourcing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Drug Discovery Outsourcing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Drug Discovery Outsourcing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Charles River Laboratories
  • 2. Curia Global, Inc.
  • 3. Dalton Pharma Services
  • 4. Eurofins DiscoverX Products
  • 5. Evotec SE
  • 6. GenScript Biotech Corporation
  • 7. Jubilant Biosys Ltd.
  • 8. Laboratory Corporation of America Holdings
  • 9. Merck & Co., Inc.
  • 10. Oncodesign Precision Medicine
  • 11. PPD Inc.
  • 12. Thermo Fisher Scientific Inc.
  • 13. WuXi AppTec
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦